These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17627553)

  • 1. Targeting the liver in the metabolic syndrome: evidence from animal models.
    Petruzzelli M; Lo Sasso G; Portincasa P; Palasciano G; Moschetta A
    Curr Pharm Des; 2007; 13(21):2199-207. PubMed ID: 17627553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dietary regulation of nuclear receptors in obesity-related metabolic syndrome.
    Kawada T; Goto T; Hirai S; Kang MS; Uemura T; Yu R; Takahashi N
    Asia Pac J Clin Nutr; 2008; 17 Suppl 1():126-30. PubMed ID: 18296319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes.
    Lewis GF; Carpentier A; Adeli K; Giacca A
    Endocr Rev; 2002 Apr; 23(2):201-29. PubMed ID: 11943743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
    Højlund K
    Dan Med J; 2014 Jul; 61(7):B4890. PubMed ID: 25123125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
    Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R
    Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver and insulin resistance: New wine in old bottle!!!
    Patel BM; Goyal RK
    Eur J Pharmacol; 2019 Nov; 862():172657. PubMed ID: 31499040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome.
    Jornayvaz FR; Samuel VT; Shulman GI
    Annu Rev Nutr; 2010 Aug; 30():273-90. PubMed ID: 20645852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diabetes and the metabolic syndrome].
    Yamauchi T; Kadowaki T
    Nihon Yakurigaku Zasshi; 2006 Sep; 128(3):133-40. PubMed ID: 16971775
    [No Abstract]   [Full Text] [Related]  

  • 9. Alteration of Liver Peroxisomal and Mitochondrial Functionality in the NZO Mouse Model of Metabolic Syndrome.
    Knebel B; Göddeke S; Hartwig S; Hörbelt T; Fahlbusch P; Al-Hasani H; Jacob S; Koellmer C; Nitzgen U; Schiller M; Lehr S; Kotzka J
    Proteomics Clin Appl; 2018 Jan; 12(1):. PubMed ID: 29068532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adiponectin and PPARγ: cooperative and interdependent actions of two key regulators of metabolism.
    Astapova O; Leff T
    Vitam Horm; 2012; 90():143-62. PubMed ID: 23017715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine functions of adipose tissue.
    Waki H; Tontonoz P
    Annu Rev Pathol; 2007; 2():31-56. PubMed ID: 18039092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metabolic syndrome: from insulin resistance to adipose tissue dysfunction].
    Camera A; Hopps E; Caimi G
    Minerva Med; 2008 Jun; 99(3):307-21. PubMed ID: 18497727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance.
    Grundy SM
    Clin Cornerstone; 2006; 8 Suppl 1():S21-7. PubMed ID: 16903166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of adipokines in formation of lipid and carbohydrate metabolic disorders in patients with cardiovascular disease].
    Kravchun P; Kadykova O; Gabisoniia T
    Georgian Med News; 2012 Dec; (213):26-31. PubMed ID: 23293229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adipocytokins, obesity and development of type 2 diabetes].
    Lacquemant C; Vasseur F; Leprêtre F; Froguel P
    Med Sci (Paris); 2005 Dec; 21 Spec No():10-8. PubMed ID: 16598899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
    Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
    Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adiponectin: A potential therapeutic target for metabolic syndrome.
    Ghadge AA; Khaire AA; Kuvalekar AA
    Cytokine Growth Factor Rev; 2018 Feb; 39():151-158. PubMed ID: 29395659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease.
    Meshkani R; Adeli K
    Clin Biochem; 2009 Sep; 42(13-14):1331-46. PubMed ID: 19501581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New peptides players in metabolic disorders.
    Mierzwicka A; Bolanowski M
    Postepy Hig Med Dosw (Online); 2016 Aug; 70(0):881-6. PubMed ID: 27594563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.